Perceptive Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.8M Sell
11,634,211
-960,000
-8% -$2.53M 0.33% 57
2026
Q1
$48.9M Hold
12,594,211
0.95% 26
2025
Q4
$24.6M Hold
12,594,211
0.44% 56
2025
Q3
$10.6M Hold
12,594,211
0.31% 54
2025
Q2
$9.13M Hold
12,594,211
0.34% 55
2025
Q1
$10.8M Hold
12,594,211
0.38% 52
2024
Q4
$21.2M Hold
12,594,211
0.58% 39
2024
Q3
$35.9M Hold
12,594,211
0.76% 36
2024
Q2
$29.5M Hold
12,594,211
0.71% 43
2024
Q1
$37M Hold
12,594,211
0.65% 49
2023
Q4
$37.7M Buy
12,594,211
+3,483,060
+38% +$9.97M 0.84% 36
2023
Q3
$28.8M Hold
9,111,151
0.96% 32
2023
Q2
$35.3M Hold
9,111,151
1.02% 31
2023
Q1
$25.2M Hold
9,111,151
0.75% 39
2022
Q4
$16.4M Hold
9,111,151
0.46% 47
2022
Q3
$19.3M Hold
9,111,151
0.56% 44
2022
Q2
$24.5M Hold
9,111,151
0.77% 31
2022
Q1
$39.5M Hold
9,111,151
0.79% 34
2021
Q4
$47.2M Buy
9,111,151
+200,000
+2% +$1.07M 0.73% 34
2021
Q3
$54.7M Hold
8,911,151
0.79% 31
2021
Q2
$90M Buy
+8,911,151
New +$96.5M 1.17% 22

Other funds holding NAUT

Perceptive Advisors's NAUT Position: Q2 2026 in Review

Perceptive Advisors reduced its Nautilus Biotechnolgy (NAUT) stake by 7.6% in Q2 2026, selling an estimated $2.53M and leaving 11,634,211 shares worth $21.8M. The position accounts for 0.33% of the portfolio, ranked #57.

Perceptive Advisors first reported a position in NAUT in Q2 2021 and has held it in 21 quarters since. The position peaked at $90M in Q2 2021. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Perceptive Advisors held 11,634,211 shares of Nautilus Biotechnolgy worth $21.8M as of Q2 2026.
  • Perceptive Advisors sold 960,000 Nautilus Biotechnolgy shares in Q2 2026, an estimated $2.53M.
  • Nautilus Biotechnolgy made up 0.33% of Perceptive Advisors's portfolio in Q2 2026, its #57 holding.
  • Perceptive Advisors first reported a position in Nautilus Biotechnolgy in Q2 2021 and has held it in 21 quarters since.
  • Perceptive Advisors's Nautilus Biotechnolgy position peaked at $90M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.